AmideBio has leveraged its core manufacturing technology to pursue a series of therapeutic targets that include, ultrastable insulin, glucose sensing insulin, solution stable glucagon and the development of diagnostics for early detection of T1 diabetes.

DRUG CANDIDATE
TARGET AREA
PRECLINICAL
IND  STUDIES
CLINICAL TRIALS
AB-SCI-177
Ultraconcentrated insulin
T2 DIABETES

AB-GLC-035
Solution Stable Glucagon
HYPERINSULINISM

AB-GSI-084
Glucose Sensing Insulin
T1 T2 DIABETES

AB-DIG-014
Early Diagnostic
T1 DIAGNOSTIC